Увійти

Готові списки джерел за темами / Aminobisphosphonate / Статті в журналах

Статті в журналах з теми "Aminobisphosphonate"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Aminobisphosphonate.

Автор: Grafiati

Опубліковано: 10 грудня 2022

Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Aminobisphosphonate".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Das, Hiranmoy, Lisheng Wang, Arati Kamath та Jack F. Bukowski. "Vγ2Vδ2 T-cell receptor–mediated recognition of aminobisphosphonates". Blood 98, № 5 (1 вересня 2001): 1616–18. http://dx.doi.org/10.1182/blood.v98.5.1616.

Повний текст джерела

Анотація:

Aminobisphosphonates, potent derivatives of bisphosphonates, are frequently used for the treatment of conditions such as osteoporosis and bone metastases that are characterized by excessive osteoclastic bone resorption. Using T-cell receptor (TCR) transfer studies, we show that recognition of antigenic aminobisphosphonates that are known to stimulate human γδ T cells in vitro and in vivo (potency: risedronate > alendronate > pamidronate) requires expression of the Vγ2Vδ2 TCR and is thus Vγ2Vδ2 TCR–dependent. Myeloma cells or monocytes pulsed with risedronate and then washed rendered these target cells sensitive to lysis by a Vγ2Vδ2 T-cell clone or cell line. These results suggest that Vγ2Vδ2 TCR–dependent recognition leading to direct cytolysis of aminobisphosphonate-sensitized osteoclast or tumor targets may be a mechanism whereby aminobisphosphonate treatment of cancers metastatic to bone decreases osteoclastic activity and tumor burden and also may account for the decreased osteoclastic activity associated with successful treatment of osteoporosis.

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Endo, Yasuo, Masahiko Shibazaki, Kouji Yamaguchi, Masanori Nakamura, and Hiroshi Kosugi. "Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate." British Journal of Pharmacology 126, no. 4 (February 1999): 903–10. http://dx.doi.org/10.1038/sj.bjp.0702367.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Kantoci, Darko, J. Kane Denike, and William J. Wechter. "Synthesis of Aminobisphosphonate." Synthetic Communications 26, no. 10 (May 1996): 2037–43. http://dx.doi.org/10.1080/00397919608003560.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

KANTOCI, D., J. K. DENIKE, and W. J. WECHTER. "ChemInform Abstract: Synthesis of Aminobisphosphonate." ChemInform 27, no. 34 (August 5, 2010): no. http://dx.doi.org/10.1002/chin.199634177.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Cairo, Cristiana, Bertrand Sagnia, Giulia Cappelli, Rose Leke, Robert Leke, Vittorio Colizzi та C. Pauza. "Repertoire selection and effector functions of neonatal γδ T cells (85.12)". Journal of Immunology 184, № 1_Supplement (1 квітня 2010): 85.12. http://dx.doi.org/10.4049/jimmunol.184.supp.85.12.

Повний текст джерела

Анотація:

Abstract The neonatal T cell repertoire includes a low frequency of Vγ2Vδ2 T cells. This population is poorly reactive to phosphoantigens or aminobisphosphonates, compared to the adult repertoire in blood. The neonatal Vδ2 cell population also shows a reduced proportion of Vγ2-Jγ1.2 rearrangements; this TCR chain combines with the Vδ2 to endow phosphoantigen responsiveness. We are interested in how the neonatal repertoire is selected to produce the dominant Vγ2-Jγ1.2 rearrangement seen in adults. IL-15 did not improve responses to stimulation, but improved survival. Both IL-2 and IL-15 up-regulated NK receptors and perforin production, although IL-2 preferentially down-regulated CD27 expression, that may be linked to the development of cytotoxicity. Curiously, aminobisphosphonate stimulation in a single round selected a Vγ2 repertoire similar to adults. Thus, neonatal γδ T cells found in cord blood are an attractive model for understanding the genesis of cytotoxic T cells lineages.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Kuźnik, Anna, Dominika Kozicka, Wioleta Hawranek, Karolina Socha та Karol Erfurt. "One-Pot and Catalyst-Free Transformation of N-Protected 1-Amino-1-Ethoxyalkylphosphonates into Bisphosphonic Analogs of Protein and Non-Protein α-Amino Acids". Molecules 27, № 11 (2 червня 2022): 3571. http://dx.doi.org/10.3390/molecules27113571.

Повний текст джерела

Анотація:

Herein, we describe the development of one-pot transformation of α-ethoxy derivatives of phosphorus analogs of protein and non-protein α-amino acids into biologically important N-protected 1-aminobisphosphonates. The proposed strategy, based on the three-component reaction of 1-(N-acylamino)-1-ethoxyphosphonates with triphenylphosphonium tetrafluoroborate and triethyl phosphite, facilitates good to excellent yields under mild reaction conditions. The course of the reaction was monitored by 31P NMR spectroscopy, allowing the identification of probable intermediate species, thus making it possible to propose a reaction mechanism. In most cases, there is no need to use a catalyst to provide transformation efficiency, which increases its attractiveness both in economic and ecological terms. Furthermore, we demonstrate that the one-pot procedure can be successfully applied for the synthesis of structurally diverse N-protected bisphosphonic analogs of α-amino acids. As shown, the indirect formation of the corresponding phosphonium salt as a reactive intermediate during the conversion of 1-(N-acylamino)-1-ethoxyphosphonate into a 1-aminobisphosphonate derivative is a crucial component of the developed methodology.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Meraviglia, Serena, Carmela La Mendola, Valentina Orlando, Francesco Scarpa, Giuseppe Cicero та Francesco Dieli. "Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies". Oncology Reviews 4, № 4 (14 грудня 2011): 211. http://dx.doi.org/10.4081/oncol.2010.211.

Повний текст джерела

Анотація:

The potent anti-tumor activities of γδ T cells, their ability to produce pro-inflammatory cytokines, and their strong cytolytic activity have prompted the development of protocols in which γδ agonists or ex vivo-expanded γδ cells are administered to tumor patients. γδ T cells can be selectively activated by either synthetic phosphoantigens or by drugs that enhance their accumulation into stressed cells as aminobisphosphonates, thus offering new avenues for the development of γδ T cell-based immunotherapies. The recent development of small drugs selectively activating Vγ9Vδ2 T lymphocytes, which upregulate the endogenous phosphoantigens, has enabled the investigators to design the experimental approaches of cancer immunotherapies; several ongoing phase I and II clinical trials are focused on the role of the direct bioactivity of drugs and of adoptive cell therapies involving phosphoantigen- or aminobisphosphonate-activated Vγ9Vδ2 T lymphocytes in humans. In this review, we focus on the recent advances in the activation/expansion of γδ T cells in vitro and in vivo that may represent a promising target for the design of novel and highly innovative immunotherapy in patients with hematologic malignancies.<br />

Стилі APA, Harvard, Vancouver, ISO та ін.

8

NAKASHIMA, Mitsuyoshi, Mitsutaka KANAMARU, and Norihiro TAKENAGA. "Phase I Study of Alendronate, a New Aminobisphosphonate." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 26, no. 2 (1995): 475–89. http://dx.doi.org/10.3999/jscpt.26.475.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Liu, Chia-Yuan, Po-Sheng Yang, Shih-Ping Cheng, Yu-Chuen Huang, Jie-Jen Lee, Chun-Chuan Ko, Hui-Ru Shieh, and Yu-Jen Chen. "Zoledronic acid, an aminobisphosphonate, prolongs survival of skin allografts." Clinical & Investigative Medicine 35, no. 4 (August 4, 2012): 165. http://dx.doi.org/10.25011/cim.v35i4.17144.

Повний текст джерела

Анотація:

Purpose: Zoledronic acid (ZOL), an effective nitrogen-containing bisphosphonate used to prevent excessive bone loss in clinical practice, has been shown to affect the development of dendritic cells by redirecting differentiation toward a state of atypical maturation. The study was aimed to examine whether ZOL can reduce acute rejection of skin allografts. Methods: A skin transplantation model using C57BL/6 to BALB/c mice was used. ZOL was injected intraperitoneally into transplant recipients post-surgically. Graft survival, body weight, leukocyte count, hepatic and renal functions were assessed. Results: ZOL treatment significantly prolonged skin allograft survival in mice. In terms of toxicity, there were no significant differences in body weight, leukocyte count, plasma alanine aminotransferase or creatinine levels between the ZOL-treated and control groups. Histopathology showed that the loss of skin integrity seen in control group was prevented by ZOL treatment. In draining lymph nodes and spleen, the number and clustering extent of mononuclear cells were markedly declined by ZOL treatment. The plasma IL-6 levels were reduced by treatment of ZOL. Conclusion: ZOL can prolong skin allograft survival without major toxicity.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Moon, Myung-Sang, Ki-Tae Kwon, Chang-Won Ha, Sung-Soo Kim, Sung Sim Kim, and Hanlim Moon. "BONE HISTOLOGY OF PATIENTS WITH ALENDRONATE-MEDIATED FRACTURED BONE — A NEW ENTITY OF ATYPICAL OSTEOMALACIA." Journal of Musculoskeletal Research 17, no. 03 (September 2014): 1450011. http://dx.doi.org/10.1142/s0218957714500110.

Повний текст джерела

Анотація:

Based on the pharmaco-physiology of the aminobisphosphonates, it could be speculated that bisphosphonates could induce not only the osteopetrotic bone disease because of their selective suppression of osteoclastic activity, but also could affect directly or indirectly the endocrine system, local factors, and also the bone metabolic turnover. Consequently, the bone fragility could be rather produced by long-term aminobisphosphonate therapy. Bisphosphonate-mediated bone disease was labeled by Odvina et al. in 2005 [Odvina CV, Zerwerth JE, Rao DS et al. Severely suppressed bone turnover; a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294–1301, 2005.] as the "severely suppressed bone turnover (SSBT)" on the metabolic turnover basis. However, such definition could contain various drug-induced bone diseases, and did not indicate any particular condition, induced by the bisphosphonate. The term "SSBT" is thought not solely to be based on its histology, and seems rather a clinical term applicable to the various drug-induced bone diseases. Therefore, the current authors attempted to characterize the bisphosphonate-mediated bone disease on the basis of the combined image and histological studies, and finally concluded that the prolonged bisphosphonate therapy could produce an atypical osteomalacic bone disease. (osteosclerosis of osteomalacia) which leads to fragility fracture. It is puzzling as to why malacia rather than petrosis develops in the skeleton.

Стилі APA, Harvard, Vancouver, ISO та ін.

11

López-Francés, Adrián, Francisco Palacios, Aitor Maestro, and Javier Vicario. "Diethyl(benzamido(diisopropoxyphosphoryl)methyl)phosphonate." Molbank 2022, no. 3 (August 11, 2022): M1424. http://dx.doi.org/10.3390/m1424.

Повний текст джерела

Анотація:

Bisphosphonates are widely used in medicine and related areas, mainly for the treatment of bone diseases, such as osteoporosis. However, their synthesis is usually performed under harsh reaction conditions. In order to overcome this limitation, the present work illustrates a new synthetic route to access the title α-aminobisphosphonate in milder reaction conditions using α-phosphorylated imines as key intermediates.

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Bachler, Patricia R., Michael D. Schulz, Chelsea A. Sparks, Kenneth B. Wagener, and Brent S. Sumerlin. "Aminobisphosphonate Polymers via RAFT and a Multicomponent Kabachnik-Fields Reaction." Macromolecular Rapid Communications 36, no. 9 (March 24, 2015): 828–33. http://dx.doi.org/10.1002/marc.201500060.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

HARINCK, H. I. J., OLAV L. M. BIJVOET, H. J. BLANKSMA, and P. J. DAHLINGHAUS-NIENHUYS. "Efficacious Management with Aminobisphosphonate (APD) in Paget??s Disease of Bone." Clinical Orthopaedics and Related Research &NA;, no. 217 (April 1987): 79???98. http://dx.doi.org/10.1097/00003086-198704000-00010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Ehrick, Robin S., Marcello Capaccio, David A. Puleo, and Leonidas G. Bachas. "Ligand-Modified Aminobisphosphonate for Linking Proteins to Hydroxyapatite and Bone Surface." Bioconjugate Chemistry 19, no. 1 (January 2008): 315–21. http://dx.doi.org/10.1021/bc700196q.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Price, R., A. Fenton, N. Kent, D. Gutteridge, C. Bhagat, B. Stuckey, and R. Retallack. "Intravenous aminobisphosphonate (APD) in Paget's disease: Clinical, biochemical and histomorphometric responses." Bone and Mineral 10, no. 3 (September 1990): S318. http://dx.doi.org/10.1016/0169-6009(90)90377-r.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Roldán, EJA, OJ Dearossi, M. Gongalves, JC Barreira, D. Messina, EM Kerzberg, E. Montuori, and A. Pérez Lloret. "Human serum kinetics of a new aminobisphosphonate labelled with 99m Tc." Bone and Mineral 17 (April 1992): S18. http://dx.doi.org/10.1016/0169-6009(92)92285-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Fenton, Anna J., Donald H. Gutteridge, G. Nell Kent, Roger I. Price, Robert W. Retallack, Chotoo I. Bhagat, Graeme K. Worth, et al. "Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses." Clinical Endocrinology 34, no. 3 (March 1991): 197–204. http://dx.doi.org/10.1111/j.1365-2265.1991.tb00294.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Tan, Paul L. J., June M. Katz, Ruth Ames, David E. Caughey, Harley D. Gray, H. Kaye Ibbertson, and James D. Watson. "Aminobisphosphonate inhibition of interleukin-1—induced bone resorption in mouse calvariae." Arthritis & Rheumatism 31, no. 6 (June 1988): 762–68. http://dx.doi.org/10.1002/art.1780310610.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Veena, HR, and Deepak Prasad. "Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects." Journal of Indian Society of Periodontology 14, no. 1 (2010): 40. http://dx.doi.org/10.4103/0972-124x.65438.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Nakamura, Masanori, Hideki Yagi, Yasuo Endo, Hiroshi Kosugi, Tadashi Ishi, and Tsunetoshi Itoh. "A time kinetic study of the effect of aminobisphosphonate on murine haemopoiesis." British Journal of Haematology 107, no. 4 (December 1999): 779–90. http://dx.doi.org/10.1046/j.1365-2141.1999.01774.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Chen, Yu-Jen, K. S. Clifford Chao, Yuh-Cheng Yang, Ming-Ling Hsu, Chin-Ping Lin, and Yu Yawn Chen. "Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells." Immunopharmacology and Immunotoxicology 31, no. 3 (April 2009): 499–508. http://dx.doi.org/10.1080/08923970902814103.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Weinstein, Robert S. "Long-Term Aminobisphosphonate Treatment of Fibrous Dysplasia: Spectacular Increase in Bone Density." Journal of Bone and Mineral Research 12, no. 8 (August 1, 1997): 1314–15. http://dx.doi.org/10.1359/jbmr.1997.12.8.1314.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Callan, John F., Sukanta Kamila, Narinder Singh, Ray C. Mulrooney, Martha MacKay, Maedhbh C. Cronin, John Dunn та David G. Durham. "A new class of fluorescent chemosensors based on the β-aminobisphosphonate receptor". Supramolecular Chemistry 21, № 7 (22 вересня 2009): 643–49. http://dx.doi.org/10.1080/10610270802709352.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Richards, P. J., N. Amos, A. S. Williams, and B. D. Williams. "Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo." Rheumatology 38, no. 10 (October 1999): 984–91. http://dx.doi.org/10.1093/rheumatology/38.10.984.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Caccamo, Nadia, Serena Meraviglia, Francesco Scarpa, Carmela La Mendola, Daniele Santini, Cesira T. Bonanno, Gabriella Misiano, Francesco Dieli та Alfredo Salerno. "Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no more". Expert Opinion on Biological Therapy 8, № 7 (12 червня 2008): 875–83. http://dx.doi.org/10.1517/14712598.8.7.875.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Keller, R. Kennedy, and Steven J. Fliesler. "Mechanism of Aminobisphosphonate Action: Characterization of Alendronate Inhibition of the Isoprenoid Pathway." Biochemical and Biophysical Research Communications 266, no. 2 (December 1999): 560–63. http://dx.doi.org/10.1006/bbrc.1999.1849.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Gutteridge, D. H., L. C. Ward, G. O. Stewart, R. W. Retallack, R. K. Will, R. L. Prince, A. Criddle, et al. "Paget's disease: Acquired resistance to one aminobisphosphonate with retained response to another." Journal of Bone and Mineral Research 14, S2 (November 1999): 79–84. http://dx.doi.org/10.1002/jbmr.5650140216.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Rendina, Domenico, Gianpaolo De Filippo, Daniela Merlotti, Marco Di Stefano, Christian Mingiano, Alfonso Giaquinto, Marco Evangelista, et al. "Increased Prevalence of Nephrolithiasis and Hyperoxaluria in Paget Disease of Bone." Journal of Clinical Endocrinology & Metabolism 105, no. 12 (August 22, 2020): e4430-e4438. http://dx.doi.org/10.1210/clinem/dgaa576.

Повний текст джерела

Анотація:

Abstract Context Nephrolithiasis (NL) and primary hyperparathyroidism (HPTH) are metabolic complications of Paget disease of bone (PDB), but recent data regarding their prevalence in PDB patients are lacking. Objectives Study 1: To compare the prevalence of primary HPTH and NL in 708 patients with PDB and in 1803 controls. Study 2: To evaluate the prevalence of NL-metabolic risk factors in 97 patients with PDB and NL, 219 PDB patients without NL, 364 NL patients without PDB, and 219 controls, all of them without HPTH. Design Cross-sectional multicentric study. Setting Italian referral centers for metabolic bone disorders. Participants Patients with PDB from the Associazione Italiana malati di osteodistrofia di Paget registry. Participants in the Olivetti Heart and the Siena Osteoporosis studies. Main Outcome Measures HPTH; NL; NL-metabolic risk factors. Results Patients with PDB showed higher prevalence of primary HPTH and NL compared with controls (P < 0.01). The NL recurrence occurs more frequently in patients with polyostotic PDB. About one-half of patients with PDB but without NL showed 1 or more NL-related metabolic risk factors. The hyperoxaluria (HyperOx) prevalence was higher in patients with PDB and NL compared with patients with NL but without PDB and in patients with PDB without NL compared with controls (P = 0.01). Patients with PDB and HyperOx showed a longer lapse of time from the last aminobisphosphonate treatment. Conclusions NL and HPTH are frequent metabolic complication of PDB. The NL occurrence should be evaluated in patients with PDB, particularly in those with polyostotic disease and/or after aminobisphosphonate treatment to apply an adequate prevention strategy.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Ho, Andrew YY, and Annie WC Kung. "Efficacy and Tolerability of Alendronate Once Weekly in Asian Postmenopausal Osteoporotic Women." Annals of Pharmacotherapy 39, no. 9 (September 2005): 1428–33. http://dx.doi.org/10.1345/aph.1e580.

Повний текст джерела

Анотація:

BACKGROUND: Osteoporosis has become a major health problem worldwide, and the incidence is rising in Asian countries. The aminobisphosphonates are potent inhibitors of bone resorption and are currently the mainstay of treatment for postmenopausal osteoporosis. Dosing frequency will likely affect tolerability and adherence to treatment. OBJECTIVE: To assess the tolerability and efficacy of a once-weekly aminobisphosphonate preparation in improving bone mineral density (BMD) and bone turnover markers in osteoporotic Asian women. METHODS: Chinese postmenopausal women with osteoporosis were randomized to receive either alendronate 70 mg once weekly plus calcium carbonate 500 mg daily (n = 29%) or calcium carbonate 500 mg daily (n = 29%) for one year. BMD was measured by dual energy X-ray absorptiometry. Markers of bone formation and bone resorption included plasma total alkaline phosphatase and urine N-telopeptides. RESULTS: Treatment with alendronate 70 mg once weekly for one year resulted in significant BMD improvement of 6.1% at the spine, 5.6% at the femoral neck, and 3.5% at the total hip. There was no significant change in the BMD values in the calcium group (spine 1.4%, femoral neck −0.2%, total hip 0%). The BMD response in the alendronate group was significantly different from that in the calcium group at all time points, and the difference was detectable as early as after 3 months of treatment (ANOVA p < 0.001%). The changes remained significant after adjusting for age, age at menarche, and years since menopause (p < 0.001%). Similarly, the reductions in bone markers at 12 months were significantly different between the 2 treatment groups (plasma total alkaline phosphatase: alendronate 27.9%, calcium 5.4%; urine N-telopeptide: alendronate 55.6%, calcium 11.2%; both p < 0.001%). The alendronate regimen was well tolerated, without significant adverse events. CONCLUSIONS: The results confirmed that once-weekly alendronate was efficacious in increasing BMD and reducing bone turnover and was well tolerated in Asian women.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Yamamoto, Michiko, Angelo Markatos, J. Gregory Seedor, Patricia Masarachia, Michael Gentile, Gideon A. Rodan, and Raffaella Balena. "The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats." Calcified Tissue International 53, no. 4 (October 1993): 278–82. http://dx.doi.org/10.1007/bf01320914.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

TAN, P. L. J., R. AMES, S. YEOMAN, H. K. IBBERTSON, and D. E. CAUGHEY. "EFFECTS OF AMINOBISPHOSPHONATE INFUSION ON BIOCHEMICAL INDICES OF BONE METABOLISM IN RHEUMATOID ARTHRITIS." Rheumatology 28, no. 4 (1989): 325–28. http://dx.doi.org/10.1093/rheumatology/28.4.325.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Landman, J. O., N. A. T. Hamdy, E. K. J. Pauwels, and S. E. Papapoulos. "Continuous aminobisphosphonate (pamidronate) treatment of osteoporosis; maintained beneficial effects beyond 3 years of therapy." Osteoporosis International 6, S1 (January 1996): 265. http://dx.doi.org/10.1007/bf02500597.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Hooper, M., P. Clifton-Bligh, G. Marel, F. Lang, J. Tancred, D. McDowall, and L. Forman. "A single day intravenous infusion of aminobisphosphonate (pamidronate) for the treatment of paget's disease." Bone and Mineral 17 (April 1992): 224. http://dx.doi.org/10.1016/0169-6009(92)92231-e.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Hooper, M., P. Clifton-Bligh, G. Marel, F. Lang, J. Tancre, D. McDowall, and L. Forman. "A single day intravenous infusion of aminobisphosphonate (pamidronate) for the treatment of Paget's disease." Bone and Mineral 17 (April 1992): S30. http://dx.doi.org/10.1016/0169-6009(92)92326-l.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Benelli, Roberto, Delfina Costa, Laura Salvini, Samuele Tardito, Francesca Tosetti, Federico Villa, Maria Raffaella Zocchi, and Alessandro Poggi. "Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab." Journal for ImmunoTherapy of Cancer 10, no. 12 (December 2022): e005660. http://dx.doi.org/10.1136/jitc-2022-005660.

Повний текст джерела

Анотація:

BackgroundAntibody-drug conjugates (ADC) are essential therapeutic options to treat solid and hematological cancers. The anti-epidermal growth factor-receptor (EGFR) antibody cetuximab (Cet) is used for the therapy of colorectal carcinoma (CRC). Anti-CRC Vδ2 cytolytic T lymphocytes can be elicited by the priming of tumor cells with the aminobisphosphonate zoledronic acid (ZA) and consequent presentation of isopentenyl pyrophosphates through butyrophilin (BTN) family members such as BTN3A1 and BTN2A1. A major drawback that impairs the targeting of ZA to CRC is the bone tropism of aminobisphosphonates.MethodsThe phosphoric group of ZA was linked to free amino groups of Cet in the presence of imidazole following the labeling of phosphoric groups of DNA to amino groups of proteins. The generation of Cet-ZA ADC was confirmed by matrix assisted laser desorption ionization mass spectrometry and inductively coupled plasma-mass spectrometry analysis. Thirteen CRC organoids were obtained with a chemically defined serum-free medium in Geltrex domes. Proliferation and activation of cytolytic activity against CRC organoids by Vδ2 T cells was detected with flow cytometry, crystal violet and cytotoxic probe assays and image analysis. Immunohistochemistry and quantification of BTN3A1 or BTN2A1 expression and the number of tumor infiltrating Vδ2 T cells in CRC were performed by automatic immunostaining, whole slide scanning and computerized analysis of digital pathology imaging.ResultsThe novel ADC Cet-ZA was generated with a drug antibody ratio of 4.3 and displayed a reactivity similar to the unconjugated antibody. More importantly, patient-derived CRC organoids, or CRC tumor cell suspensions, could trigger the expansion of Vδ2 T cells from peripheral blood and tumor infiltrating lymphocytes when primed with Cet-ZA. Furthermore, Cet-ZA triggered Vδ2 T cell-mediated killing of CRC organoids. The expression of BTN3A1 and BTN2A1 was detected not only in CRC organoids but also in CRC specimens, together with a considerable amount of tumor infiltrating Vδ2 T cells.ConclusionsThese findings are proof of concept that the Cet-ZA ADC can be used to target specifically CRC organoids and may suggest a new experimental approach to deliver aminobisphosphonates to EGFR+solid tumors.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Josse, S., C. Faucheux, A. Soueidan, G. Grimandi, D. Massiot, B. Alonso, Pascal Janvier, et al. "A Novel Drug Delivery System for Bisphosphonates: Innovative Strategy for Local Treatment of Bone Resorption." Key Engineering Materials 284-286 (April 2005): 399–402. http://dx.doi.org/10.4028/www.scientific.net/kem.284-286.399.

Повний текст джерела

Анотація:

One type of potent aminobisphosphonate (Zoledronate) has been chemically associated onto b-tricalcium phosphate [b-TCP] and calcium deficients apatite [CDA]. Two different association modes have been observed, according to the nature of the Calcium Phosphate [CaP] support and/or the initial concentration of the Zoledronate solution. b-TCP appears to promote Zoledronate-containing crystals formation. On the other hand, at concentrations < 0.05 mol.L-1 CDA seems to undergo chemisorption of the drug through a surface adsorption process, due to PO3 for PO4 exchange, which is well described by Freundlich equations. At concentrations > 0.05 mol.L-1, crystalline needles of a Zoledronate complex form onto the CDA surface. The ability of CDA to release Zoledronate, resulting in the inhibition of osteoclastic activity, was shown using a specific in vitro bone resorption model.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Lorimier, L. P., T. M. Fan, S. C. Charney, H. I. Lacoste, D. A. Heller, M. M. Endicott, and C. H. Souza. "Monitoring response to aminobisphosphonate therapy in canine osteosarcoma using dual energy x-ray absorptiometry (dexa)." Veterinary and Comparative Oncology 2, no. 2 (June 2004): 101–2. http://dx.doi.org/10.1111/j.1476-5810.2004.0045e.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Adami, Silvano, Vania Braga, Giancesare Guidi, Davide Gatti, Daniela Gerardi, and Elena Fracassi. "Chronic Intravenous Aminobisphosphonate Therapy Increases High-Density Lipoprotein Cholesterol and Decreases Low-Density Lipoprotein Cholesterol." Journal of Bone and Mineral Research 15, no. 3 (February 18, 2010): 599–604. http://dx.doi.org/10.1359/jbmr.2000.15.3.599.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Marcuzzi, Annalisa, Alberto Tommasini, Sergio Crovella, and Alessandra Pontillo. "Natural isoprenoids inhibit LPS-induced-production of cytokines and nitric oxide in aminobisphosphonate-treated monocytes." International Immunopharmacology 10, no. 6 (June 2010): 639–42. http://dx.doi.org/10.1016/j.intimp.2010.03.008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Gibbons, C. L. M. H., M. Petra, R. Smith, and N. A. Athanasou. "Bisphosphonate Treatment of Benign Multifocal and Unifocal Osteolytic Tumours of Bone." Sarcoma 7, no. 1 (2003): 35–41. http://dx.doi.org/10.1080/1357714031000114165.

Повний текст джерела

Анотація:

Growth of benign tumours and tumour-like lesions of bone results in osteolysis which may cause pathological fracture. Bisphosphonates are anti-osteolytic agents which have proved effective in the treatment of number of osteolytic conditions. In this study we report the results of treatment with the aminobisphosphonate, pamidronate, of three benign osteolytic tumours of bone, two cases of fibrous dysplasia and one of Langerhans cell histiocytosis. In all three cases there was clinical and radiological improvement following treatment. Radiologically, bone lesions did not exhibit progressive enlargement. Two cases of fibrous dysplasia also showed features suggestive of increased bone formation. These findings indicate that bisphosphonates are likely to be useful in controlling the osteolysis of benign tumours/tumour-like lesions of bone, particularly in those cases where surgical intervention is not possible or multifocal lesions are present.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Tu, Wenwei, Jian Zheng, Yinping Liu, Sin Fun Sia, Ming Liu, Gang Qin, Iris H. Y. Ng та ін. "The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a γδ T cell population in humanized mice". Journal of Experimental Medicine 208, № 7 (27 червня 2011): 1511–22. http://dx.doi.org/10.1084/jem.20110226.

Повний текст джерела

Анотація:

There are few antiviral drugs for treating influenza, and the emergence of antiviral resistance has further limited the available therapeutic options. Furthermore, antivirals are not invariably effective in severe influenza, such as that caused by H5N1 viruses. Thus, there is an urgent need to develop alternative therapeutic strategies. Here, we show that human Vγ9Vδ2 T cells expanded by the aminobisphosphonate pamidronate (PAM) kill influenza virus–infected cells and inhibit viral replication in vitro. In Rag2−/−γc−/− immunodeficient mice reconstituted with human peripheral mononuclear cells (huPBMCs), PAM reduces disease severity and mortality caused by human seasonal H1N1 and avian H5N1 influenza virus, and controls the lung inflammation and viral replication. PAM has no such effects in influenza virus–infected Rag2−/−γc−/− mice reconstituted with Vγ9Vδ2 T cell–depleted huPBMCs. Our study provides proof-of-concept of a novel therapeutic strategy for treating influenza by targeting the host rather than the virus, thereby reducing the opportunity for the emergence of drug-resistant viruses. As PAM has been commonly used to treat osteoporosis and Paget’s disease, this new application of an old drug potentially offers a safe and readily available option for treating influenza.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Kamila, Sukanta, John F. Callan, Ray C. Mulrooney та Moira Middleton. "A novel fluorescent chemosensor for Cu(II) in aqueous solution based on a β-aminobisphosphonate receptor". Tetrahedron Letters 48, № 44 (жовтень 2007): 7756–60. http://dx.doi.org/10.1016/j.tetlet.2007.09.029.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Alonzo, E., E. Bellorin-Font, R. Carlini, V. Paz-Martínez, and J. R. Weisinger. "Role of the bone in the pathogenesis of idiopathic hypercalciuria (IH): Effect of aminobisphosphonate alendronate (ALN)." Osteoporosis International 6, S1 (January 1996): 286. http://dx.doi.org/10.1007/bf02500680.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Cabillic, Florian, Olivier Toutirais, Vincent Lavoué, Cécile Thomas de La Pintière, Pascale Daniel, Nathalie Rioux-Leclerc, Bruno Turlin та ін. "Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients". Cancer Immunology, Immunotherapy 59, № 11 (26 червня 2010): 1611–19. http://dx.doi.org/10.1007/s00262-010-0887-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Balooch, Guive, Wei Yao, Joel W. Ager, Mehdi Balooch, Ravi K. Nalla, Alexandra E. Porter, Robert O. Ritchie, and Nancy E. Lane. "The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids." Arthritis & Rheumatism 56, no. 11 (2007): 3726–37. http://dx.doi.org/10.1002/art.22976.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Davison, Mario R., Leonardo Lyardet, Mariana Preliasco, Graciela Yaful, Perla Torres, Marina S. Bonanno, Gretel G. Pellegrini, and Susana N. Zeni. "Aminobisphosphonate‐treated ewes as a model of osteonecrosis of the jaw and of dental implant failure." Journal of Periodontology 91, no. 5 (December 15, 2019): 628–37. http://dx.doi.org/10.1002/jper.19-0213.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Evans, K. D., L. E. Sheppard, D. I. Grossman, S. H. Rao, R. B. Martin, and A. M. Oberbauer. "Long Term Cyclic Pamidronate Reduces Bone Growth by Inhibiting Osteoclast Mediated Cartilage-to-Bone Turnover in the Mouse." Open Orthopaedics Journal 2, no. 1 (July 14, 2008): 121–25. http://dx.doi.org/10.2174/1874325000802010121.

Повний текст джерела

Анотація:

Bisphosphonates, used to treat diseases exhibiting increased osteoclast activity, reduce longitudinal bone growth through an as yet undefined mechanism. Pamidronate, an aminobisphosphonate, was given weekly to mice at 0, 1.25, or 2.50 mg/kg/wk beginning at 4 weeks of age. At 12 weeks of age, humeral length, growth plate area, regional chondrocyte cell numbers, chondrocyte apoptosis, TRAP stained osteoclast number, and osteoclast function assessed by cathepsin K immunohistochemistry were quantified. Humeral length was decreased in pamidronate treated mice compared to vehicle control mice, and correlated with greater growth plate areas reflecting greater proliferative and hypertrophic chondrocyte cell numbers with fewer hypertrophic cells undergoing apoptosis. Pamidronate treatment increased TRAP stained osteoclast numbers yet decreased cathepsin K indicating that pamidronate repressed osteoclast maturation and function. The data suggest that long term cyclic pamidronate treatment impairs bone growth by inhibition of osteoclast maturation thereby reducing cartilage-to-bone turnover within the growth plate.

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Lee, Dae Ho. "The management of osteoporosis." Journal of Medicine and Life Science 7, no. 1 (June 1, 2010): 35–40. http://dx.doi.org/10.22730/jmls.2010.7.1.35.

Повний текст джерела

Анотація:

The prevention and treatment of osteoporosis is challenging in the elderly. Both early evatuation and proper management are very important to prevent an osteoporotic fracture. Recent development of the newer and stronger anti-resorptive agents is somewhat promising. However, many questions remain with regard to the treatment of osteoporosis; the selection of drugs, the duration of treatment, safety, side effects. Powerful aminobisphosphonate can cause osteonecrosis of the jaw. The increase in bone mineral density due to bisphosphonates accounts for only a quarier of their antifracture action. The evaluation of bone mineral density is not a perfect method. And, blood or urine markers of bone formation or resorption are easily affected by various factors. The follow-up interval after the initiation of drug treatment needs to be settled down. And, other supportive measures also need to be added to manage osteoporosis effectively. This communication discusses about such issues which have been appearing in recent publications.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Babaji, Prashant, Rajni Aggarwal, SSenthil Nathan, George Attokaran, SM Santosh Kumar, and Sharanpriya Sathnoorkar. "Comparative clinicoradiographical evaluation of effect of aminobisphosphonate (sodium alendronate) on peri-implant bone status: Controlled clinical trial." Journal of International Society of Preventive and Community Dentistry 6, no. 4 (2016): 285. http://dx.doi.org/10.4103/2231-0762.184039.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Walsh, Mairéad, Glennis White, Kenneth Romeril, Huib Buyck, Matthew Stephens, Collin Brooks та Robert Weinkove. "Innate-like T cell profile in myeloma: Severe deficiency of Vγ9Vδ2 T cells in aminobisphosphonate-treated patients". Leukemia & Lymphoma 57, № 4 (9 жовтня 2015): 977–80. http://dx.doi.org/10.3109/10428194.2015.1088653.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!